Poor long-term survival of a transplanted organ (allograft) is one of the major problems in transplant today. Circulating antibodies directed toward donor human leukocyte antigens (HLA) (donor-specific anti-HLA antibodies, DSA) are now thought to be the major cause of allograft loss. Although, we know more about these antibodies and their ability to injure the transplanted organ than we did even a decade ago, we still have much learn.
We must develop a stronger understanding of antibody mediated injury in transplant and develop new diagnostic and therapeutic tools to eradicate this problem in transplant. Here at the Terasaki Research Institute, we are working to make this happen.
At the Terasaki Research Institute, we are keenly focused on working together with transplant patients to get a better understanding of their habits, preferences, and quality of life. We want to make transplant care, transplant medications, and the entire transplant process better fit the needs of the transplant patients. We believe that we can combine the patient's needs and thoughts with our basic science research and transplant education to make a transplant recipient's life better. This requires basic scientists, clinicians, and health services researchers to work together WITH the patient. Here at the Terasaki Research Institute, we want to solve problems with the whole patient in mind.